Roche to acquire Ignyta for $1.7bn to enhance oncology portfolio

Roche Pharmaceuticals, a prominent Swiss pharmaceutical company, has entered into a definitive merger agreement to acquire Ignyta, a U.S. cancer drug maker, for $1.7 billion ... Read More